Similarly, RET L881V-driven tumours are resistant to lenvatinib, cabozantinib and vandetanib due to absence of a phenyl ring required for binding [127], and presence of this phenyl ring on RET L730V confers resistance to nintedanib, due to a hydrophobic interaction [118]. The gene discussed is RET; the disease is neoplasm.